Wealth Enhancement Advisory Services
GALT icon

Wealth Enhancement Advisory Services’s Galectin Therapeutics GALT Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$67.2K Buy
16,552
+9
+0.1% +$23 ﹤0.01% 3872
2026
Q1 		$44.2K Sell
16,543
-18,674
-53% -$56.8K ﹤0.01% 3440
2025
Q4 		$121K Sell
35,217
-20
-0.1% -$105 ﹤0.01% 3392
2025
Q3 		$168K Sell
35,237
-283
-0.8% -$1.06K ﹤0.01% 3194
2025
Q2 		$77.4K Sell
35,520
-621
-2% -$929 ﹤0.01% 3176
2025
Q1 		$44.1K Sell
36,141
-15,369
-30% -$21.6K ﹤0.01% 2860
2024
Q4 		$66.4K Buy
51,510
+16,412
+47% +$39.3K ﹤0.01% 2843
2024
Q3 		$96.5K Buy
35,098
+188
+0.5% +$462 ﹤0.01% 2564
2024
Q2 		$78.9K Buy
34,910
+16,271
+87% +$49.4K ﹤0.01% 2427
2024
Q1 		$44.5K Hold
18,639
– – ﹤0.01% 2349
2023
Q4 		$30.9K Hold
18,639
– – ﹤0.01% 2233
2023
Q3 		$35.8K Buy
+18,639
New +$30.7K ﹤0.01% 2173

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Wealth Enhancement Advisory Services's GALT Position: Q2 2026 in Review

Wealth Enhancement Advisory Services increased its Galectin Therapeutics (GALT) stake by 0.05% in Q2 2026, buying an estimated $23 and bringing the position to 16,552 shares worth $67.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3872.

Wealth Enhancement Advisory Services first reported a position in GALT in Q3 2023 and has held it in 12 quarters since. The position peaked at $168K in Q3 2025. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • Wealth Enhancement Advisory Services held 16,552 shares of Galectin Therapeutics worth $67.2K as of Q2 2026.
  • Wealth Enhancement Advisory Services bought 9 Galectin Therapeutics shares in Q2 2026, an estimated $23.
  • Galectin Therapeutics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #3872 holding.
  • Wealth Enhancement Advisory Services first reported a position in Galectin Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • Wealth Enhancement Advisory Services's Galectin Therapeutics position peaked at $168K in Q3 2025.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.